FOR IMMEDIATE RELEASE

Dipharma Acquires LogixX Pharma, Establishing a Direct Commercial Presence in the United Kingdom

Long-standing UK partner for nitisinone and sapropterin joins the Dipharma Group.

Chiasso, Switzerland, November 6, 2026 – Dipharma SA ("Dipharma"), a Swiss specialty pharmaceutical company developing improved medicines for rare diseases, today announced that it has completed the acquisition of LogixX Pharma Limited ("LogixX"), a UK specialty pharmaceutical company based in Theale, Berkshire. The transaction gives Dipharma a direct commercial presence in the United Kingdom and brings together two companies with shared values and a common focus on patients living with rare chronic diseases.

Founded in 2010, LogixX markets medicines for rare and metabolic diseases in the United Kingdom, supplying the National Health Service (NHS) and homecare providers. LogixX has been Dipharma's UK partner for nearly 10 years, commercializing Dipharma's nitisinone and, since 2023, sapropterin dihydrochloride.

The acquisition makes LogixX the platform for future Dipharma product launches in the United Kingdom, with the Group's development, regulatory and quality expertise supporting the expansion of its portfolio.

"LogixX has long been one of our most valued partners, and we are delighted that it is now part of the Dipharma Group," said Fabio Cannata, General Manager of Dipharma. *"LogixX's greatest strength is its people: over the years, the team has built deep knowledge of the UK rare chronic disease market. Combined with Dipharma's development expertise, that knowledge gives us a solid foundation to develop new therapeutic options and make them available to patients and families living with rare chronic diseases."*

"Joining Dipharma is a natural next step for LogixX," said Michael Close, Chief Executive Officer of LogixX. *"Our teams have worked side by side for years to bring Dipharma's medicines to UK patients, always with the same commitment to fairness and integrity. I am immensely proud of what we have built together: deep expertise in rare metabolic diseases and the trust of the clinicians, pharmacists and homecare teams who care for the patients relying on our medicines. As part of the Dipharma Group, we will have greater resources to broaden our portfolio and bring more treatment options to people living with rare diseases."*

LogixX will continue to operate under its existing name as a wholly owned subsidiary of Dipharma. Michael Close remains Chief Executive Officer and the LogixX team continues in its current roles.

The acquisition was completed through the purchase of LogixX's parent company, LogixX Pharma Holding Group Limited. LogixX's fertility business, which now operates as a separate company, was not part of the transaction. Financial terms were not disclosed.

About Dipharma

Dipharma SA is a Swiss specialty pharmaceutical company, developing high quality, improved, medicines for rare diseases. Dipharma SA is part of a third-generation group of family-owned companies that have grown to a global presence.

With a portfolio of specialty medicines for the treatment of Hyperphenylalaninemia, Gaucher Disease, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma SA provides improved solutions for patients affected by rare chronic diseases at an affordable cost and with a global reach.

For more information, please visit www.dipharma.ch

About LogixX

LogixX Pharma Ltd is a UK specialty pharmaceutical company founded in 2010 and based in Theale, Berkshire. LogixX markets medicines in the United Kingdom with a focus on paediatric and rare metabolic diseases with a high level on unmet medical need. The strategic and commercial functions of the company are managed by an experienced team possessing considerable pharmaceutical company experience.

LogixX is now part of the Dipharma Group.

For more information, please visit www.logixxpharma.com

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.

Dipharma SA and LogixX Pharma Ltd operate respectfully of any third-party IP rights and/or regulatory exclusivities that may exist in each specific country.

MEDIA CONTACTS

Dipharma SA
+41(0)916011700
info@dipharma.ch
www.dipharma.ch

LogixX Pharma Ltd
+44 (0)1189011747
info@logixxpharma.com
www.logixxpharma.com